Literature DB >> 22661171

Cancer control in the Asia Pacific region: current status and concerns.

Hai-Rim Shin1, Marie Clem Carlos, Cherian Varghese.   

Abstract

Cancer is becoming an increasingly important health problem in the low- and middle-income countries in the Asia Pacific region, as well as in high-income countries because of ageing populations and changes in lifestyle associated with economic development and epidemiologic transition. This paper reviews the cancer burden and control in the Asia Pacific region (limited to East Asia, South Eastern Asia and Pacific Islands countries, territories and other areas), with relevant information primarily extracted from the GLOBOCAN 2008, Cancer Incidence in Five Continents series and WHO websites. Most low- and middle-income countries have a cancer control strategy and/or an action plan; however, coverage of cancer registration is still very low and does not meet the international standard in terms of quality. Therefore, only limited data were available for the recent global estimation of cancer burden. Large variations, in both cancer incidence and mortality, were observed in the populations in the different sub-regions of Asia. The most common cancer in males is lung cancer in the Eastern and South Eastern sub-regions, while prostate cancer comes close to lung cancer in the Pacific Island countries. In females, breast cancer is the most common in all three regions. The predominance of lung, stomach, colorectal, prostate, breast and cervical cancers makes cancer control more amenable in the Asia Pacific region. Up-to-date statistics on cancer occurrence and outcome are essential for the planning and evaluation of cancer control programmes. Priority can be given to population-based cancer registration, risk reduction, especially tobacco control, and primary health care based enhancement of health care systems to diagnose and manage cancer specifically in low- and middle-income countries.

Entities:  

Mesh:

Year:  2012        PMID: 22661171     DOI: 10.1093/jjco/hys077

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  35 in total

Review 1.  Microbiota and immune responses in colon cancer: more to learn.

Authors:  Florencia McAllister; Franck Housseau; Cynthia L Sears
Journal:  Cancer J       Date:  2014 May-Jun       Impact factor: 3.360

2.  Identification of functional long non-coding RNAs in gastric cancer by bioinformatics analysis.

Authors:  Yang Li; Dongyang Ma; Tang Li; Yuan Yin
Journal:  Int J Exp Pathol       Date:  2020-07-01       Impact factor: 1.925

3.  Ataxin-3 expression correlates with the clinicopathologic features of gastric cancer.

Authors:  Li-Xia Zeng; Yong Tang; Yun Ma
Journal:  Int J Clin Exp Med       Date:  2014-04-15

4.  Role of ERK-MAPK signaling pathway in pentagastrin-regulated growth of large intestinal carcinoma.

Authors:  Jia-Ding Mao; Pei Wu; Jian-Xiong Huang; Jian Wu; Guang Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 5.  Current Status and Future Projections of Breast Cancer in Asia.

Authors:  Lei Fan; Paul E Goss; Kathrin Strasser-Weippl
Journal:  Breast Care (Basel)       Date:  2015-12-15       Impact factor: 2.860

6.  Detection of perioperative cancer antigen 72-4 in gastric juice pre- and post-distal gastrectomy and its significances.

Authors:  Lei Huang; Aman Xu; Tuanjie Li; Wenxiu Han; Shanshan Wu; Yangyi Wang
Journal:  Med Oncol       Date:  2013-07-03       Impact factor: 3.064

7.  Long Noncoding RNA PVT1 Acts as a "Sponge" to Inhibit microRNA-152 in Gastric Cancer Cells.

Authors:  Ting Li; Xiang-Ling Meng; Wen-Qi Yang
Journal:  Dig Dis Sci       Date:  2017-03-03       Impact factor: 3.199

8.  Synergistic effect of fenretinide and curcumin for treatment of non-small cell lung cancer.

Authors:  Huanxian Chen; Linmin Chen; Liang Wang; Xinhua Zhou; Judy Yuet-Wa Chan; Jingjing Li; Guozhen Cui; Simon Ming-Yuen Lee
Journal:  Cancer Biol Ther       Date:  2016-09-15       Impact factor: 4.742

9.  Financial burden of colorectal cancer treatment among patients and their families in a middle-income country.

Authors:  Meram Azzani; April Camilla Roslani; Tin Tin Su
Journal:  Support Care Cancer       Date:  2016-05-26       Impact factor: 3.603

10.  Gastric juice miR-129 as a potential biomarker for screening gastric cancer.

Authors:  Xing Yu; Lin Luo; Yibo Wu; Xiuchong Yu; Yang Liu; Xuelin Yu; Xiaoyan Zhao; Xinjun Zhang; Long Cui; Guoliang Ye; Yanping Le; Junming Guo
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.